Key Highlights
- IDEXX acquired CoVetAI on Sept 16, adding AI ambient listening and clinical documentation software; terms were not disclosed.
- On Aug 11, it launched Catalyst proBNP, the first dual-species in-clinic NT-proBNP cardiac test, on a base of nearly 80,000 Catalyst analyzers.
- Q2 Revenue rose 10% to $1.217 billion, and 2026 EPS guidance was raised to $14.69-$14.94.
- Gross Margin expanded 140 basis points to 64.0%, Operating Margin reached 35.0% and EPS rose 18% to $4.27 in the quarter.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is pushing artificial intelligence deeper into daily veterinary practice through a mix of Acquisition and product launches. On September 16, the pet diagnostics leader announced it had acquired CoVetAI Inc., known as CoVet, a provider of AI-native ambient listening and clinical workflow software that automatically captures and organizes information from consultations through treatment planning and client follow-up.
The move builds on a connected ecosystem IDEXX has spent years assembling: in-clinic analyzers that use AI to read samples, cloud-based practice management software used by more than 10,000 clinics and reference laboratory services. By adding a tool that listens to appointments and drafts clinical records, IDEXX aims to reduce paperwork for veterinarians while surfacing diagnostic insights at the moments when testing decisions are made.
The strategy has a clear commercial logic. IDEXX said the capabilities can, over time, help increase diagnostic utilization, support more personalized client communication and create capacity for clinics to see more patients. Financial terms were not disclosed.
What CoVet Brings to the Exam Room
CoVet describes itself as an AI-powered clinical copilot built by veterinary professionals. According to IDEXX's release, it automates SOAP notes, transcribes consultations and streamlines communication with pet owners, and it is used by tens of thousands of users across North America, Europe, Australia and New Zealand. It serves both multipractice corporate groups and independent clinics.
IDEXX said CoVet will be integrated into its software ecosystem, including VetConnect PLUS, while continuing to work with non-IDEXX practice management systems. IDEXX will also keep supporting other ambient scribe tools and third-party integrations, an open approach that may ease adoption among clinics using competing software.
"CoVet brings leading workflow intelligence capabilities that complement our diagnostic and software ecosystem," said IDEXX President and CEO Mike Erickson. CoVet co-founder and CEO Yannick Bloem said AI "has the potential to transform the day-to-day experience of practicing veterinary medicine." IDEXX also noted that CoVet's footprint extends to regions not currently served by its practice management systems.
AI Already Inside the Analyzers
The acquisition extends an AI strategy that already runs through IDEXX hardware. The company cited the inVue Dx Cellular Analyzer, SediVue Dx Urine Sediment Analyzer, ProCyte One Hematology Analyzer, the DecisionIQ clinical decision support tool and Web PACS imaging software as examples of AI and advanced analytics in its portfolio.
On August 11, IDEXX launched the Catalyst proBNP Test, which it called the first and only dual-species in-clinic test for NT-proBNP, a biomarker used to assess heart disease in cats and dogs. The company said heart disease affects about 1 in 6 cats and 1 in 10 dogs yet remains underassessed in general practice. The test runs on the Catalyst chemistry platform, which has a global installed base of nearly 80,000 analyzers, and IDEXX estimates the global cardiac testing opportunity at about $4 billion. The pairing is logical: software that captures a murmur noted during an exam could, in principle, prompt the clinic to run the new cardiac test during the same visit.
Second-Quarter Momentum and a Higher Outlook
The launches build on solid results. On August 4, IDEXX reported second-quarter revenue of $1.217 billion, up 10% as reported and 9% organically. Companion Animal Group Diagnostics Recurring Revenue grew 11% as reported and 10% organically, including 10% growth in the US and 12% organic growth internationally. IDEXX VetLab consumables rose 15%, reference laboratory revenue rose 11% and veterinary software, services and imaging grew 12%.
The company placed more than 1,600 inVue Dx analyzers in the quarter, lifting the installed base above 9,000. Gross margin expanded 140 basis points to 64.0%, operating margin reached 35.0% and EPS rose 18% to $4.27.
Outside companion animals, IDEXX's smaller businesses also contributed. Water testing revenue grew 15% as reported and 13% organically, while Livestock, Poultry and Dairy revenue rose 11% as reported and 9% organically, led by the Americas. The Companion Animal Group, which includes diagnostics, instruments and software, remains the dominant driver, growing 9% in the quarter.
Software is a growing part of that mix. IDEXX said veterinary software, services and diagnostic imaging revenue benefited from cloud-native software growth and a record quarter of imaging system installations. CoVet slots into this line of business, which gives IDEXX a direct commercial channel for selling AI tools alongside its existing subscriptions. IDEXX raised its 2026 EPS outlook to $14.69 to $14.94 and narrowed revenue guidance to $4.700 billion to $4.745 billion, with organic growth of 8.5% to 9.7%. It expects full-year operating margin of 32.3% to 32.5%.
How IDEXX Stacks Up in Animal Health
IDEXX competes in veterinary diagnostics with Zoetis (NASDAQ:ZTS) and Mars's Antech business, and in practice software with a range of independent vendors. Its advantage lies in the breadth of its installed base, which generates recurring consumable and service revenue. Adding workflow AI could deepen that lock-in, although ambient scribe tools are an emerging category where startups compete aggressively on price and features.
Not every product line is growing. Capital instrument revenue fell 19% in the second quarter as the company lapped the prior-year inVue Dx launch, and rapid assay revenue rose just 1%.
Risks That Could Slow Adoption
- Clinic traffic: Softer US veterinary visit volumes, a sector-wide theme in recent years, could limit testing growth even as pricing supports revenue.
- Integration and data privacy: Combining recorded consultations with diagnostic data raises integration challenges and client privacy expectations.
- Competition: Rival diagnostics providers and software startups are also adding AI features.
- Valuation sensitivity: IDEXX's premium growth profile can make its shares sensitive to any slowdown in recurring revenue.
Measuring CoVet and Catalyst proBNP Uptake Ahead
The next major checkpoint is IDEXX's third-quarter report, which the company has historically released in late October or early November; a specific date has not yet been confirmed. Investors will likely look for early uptake of Catalyst proBNP, continued inVue Dx placements, any disclosure on CoVet's contribution or integration costs, and progress toward the raised $14.69 to $14.94 EPS target.
International expansion also continues, including a September launch of taeniid tapeworm detection on the Fecal Dx antigen testing platform in the United Kingdom.






Please wait processing your request...